Europe: Food, Drugs, Healthcare, Life Sciences

Life sciences companies in Turkey navigate a complex regulatory framework governing interactions with healthcare professionals, where promotional activities face strict oversight and compliance expectations continue to intensify. While pharmaceutical promotion remains limited to healthcare professionals with mandatory transparency reporting, medical device regulations show signs of convergence in enforcement practices.

Turkey's alternative reimbursement models enable innovative pharmaceuticals to be covered outside standard pricing rules, allowing the Social Security Institution to negotiate discount rates and budget caps. A new initiative launching in January 2027 will systematically produce real-world clinical data and pharmacoeconomic evaluations for named patient program products to strengthen evidence-based reimbursement decisions.

Turkey's healthcare system underwent significant reforms in July 2025 with the adoption of Law No. 7557, introducing comprehensive updates to modernize services, enhance efficiency, and strengthen oversight mechanisms. These changes bring critical implications for life sciences companies operating in Turkey, particularly regarding physician practice limitations, advertising restrictions, pharmaceutical tracking systems, and digital consent frameworks.